Entero Therapeutics (NASDAQ:ENTO) Stock Price Up 15.5% – Should You Buy?

Shares of Entero Therapeutics, Inc. (NASDAQ:ENTO) traded up 15.5% on Friday . The company traded as high as $3.23 and last traded at $3.13. 399,212 shares changed hands during mid-day trading, an increase of 216% from the average session volume of 126,532 shares. The stock had previously closed at $2.71.

Entero Therapeutics Stock Up 15.5%

The firm’s 50 day simple moving average is $3.31 and its 200 day simple moving average is $3.30. The company has a market cap of $4.97 million, a price-to-earnings ratio of -1.85 and a beta of 1.19.

Institutional Investors Weigh In On Entero Therapeutics

A hedge fund recently bought a new stake in Entero Therapeutics stock. Virtu Financial LLC purchased a new stake in shares of Entero Therapeutics, Inc. (NASDAQ:ENTO) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 11,829 shares of the company’s stock, valued at approximately $59,000. Virtu Financial LLC owned approximately 0.74% of Entero Therapeutics as of its most recent filing with the SEC. 12.30% of the stock is owned by hedge funds and other institutional investors.

About Entero Therapeutics

Entero Therapeutics, Inc (NASDAQ: ENTO) is a clinical‐stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility‐related GI diseases.

Entero’s pipeline features multiple lead candidates in varying stages of clinical development.